Related Experiment Videos
Telithromycin: new preparation. A needless addition to the other macrolides
Abstract:
(1) Macrolides are an alternative to beta-lactam agents for treating uncomplicated community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis and throat infections. The choice of macrolides is based mainly on the risk of interactions, which is lowest with spiramycin. (2) Telithromycin is a macrolide antibiotic derived from erythromycin. It was first marketed in France in 2002, for the above indications. (3) Telithromycin is no more effective than the antibiotics with which it has been compared, namely amoxicillin and clarithromycin in non life-threatening pneumonia; amoxicillin-clavulanate and cefuroxime axetil in acute exacerbations of chronic bronchitis and acute sinusitis; and clarithromycin and phenoxymethylpenicillin (penicillin V) in pharyngotonsillitis. (4) In clinical trials, telithromycin was not more effective than comparator antibiotics on infections thought to be due to pneumococcal strains resistant to penicillin and/or erythromycin. Cases of erythromycin cross-resistance have been observed. (5) The adverse effects of telithromycin are the same as those of other macrolides, mainly gastrointestinal disturbances, headache, dizziness, and hepatotoxicity. Telithromycin also carries a risk of torsades de pointes, and seems to cause more visual problems than other macrolides. (6) Telithromycin inhibits cytochrome P450 isoenzymes, so there is a high risk of drug interactions. (7) In practice, spiramycin remains the standard option when a macrolide is indicated for the treatment of common ENT and pulmonary infections.
Insights
Telithromycin, a macrolide antibiotic, offers no superior efficacy compared to other treatments for common infections. Its adverse effects and drug interactions are similar to other macrolides, making spiramycin a preferred choice.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Therapeutics
Background:
- Macrolides serve as alternatives to beta-lactam antibiotics for various infections.
- Spiramycin presents the lowest risk of drug interactions among macrolides.
- Telithromycin, a derivative of erythromycin, was introduced for treating community-acquired pneumonia, chronic bronchitis exacerbations, sinusitis, and throat infections.
Purpose of the Study:
- To evaluate the efficacy and safety of telithromycin compared to established antibiotics.
- To assess telithromycin's effectiveness against penicillin- and erythromycin-resistant bacterial strains.
- To identify potential risks and drug interactions associated with telithromycin use.
Main Methods:
- Comparative clinical trials assessing telithromycin against amoxicillin, clarithromycin, amoxicillin-clavulanate, cefuroxime axetil, and penicillin V.
- Analysis of adverse effects, including gastrointestinal disturbances, hepatotoxicity, and cardiac risks.
- Evaluation of drug interaction profiles, particularly concerning cytochrome P450 inhibition.
Main Results:
- Telithromycin demonstrated comparable efficacy to comparator antibiotics in treating pneumonia, chronic bronchitis exacerbations, sinusitis, and pharyngotonsillitis.
- No enhanced effectiveness was observed with telithromycin against penicillin- or erythromycin-resistant pathogens.
- Adverse effects were consistent with other macrolides, with added risks of torsades de pointes and visual disturbances. Significant drug interactions due to cytochrome P450 inhibition were noted.
Conclusions:
- Telithromycin offers no significant therapeutic advantage over existing antibiotic options for common infections.
- The safety profile and drug interaction potential of telithromycin are comparable to other macrolides.
- Spiramycin remains the preferred macrolide for treating common respiratory and ENT infections due to its favorable interaction profile.